The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
Abstract
Objective: To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation. Methods: Pooled patient data from early rheumatoid arthritis (RA) clinical trials (n = 1,342) of methotrexate (MTX), tumor necrosis factor (TNF) inhibitor monotherapy (adalimumab and etanercept), and the combination of the two (adalimumab or infliximab plus MTX) were used for the primary analyses. Pooled data from clinical trials of MTX and of TNF inhibitor plus MTX in late RA (n = 712) were used for validation of the results. Disease activity was primarily assessed using the Simplified Disease Activity Index (SDAI); in addition, we calculated the Disease Activity Score 28‐joint assessment (DAS28) and the Clinical Disease Activity Index (CDAI). Associations of disease activity measures at baseline and at 1, 2, 3, and 6 months with disease activity values or disease activity states at 1 year were performed using Spearman's rank correlation, analysis of variance, and diagnostic testing procedures, including receiver operating characteristic (ROC) curve analyses, and probit analysis. Results: Correlations with SDAI values at end point were significant (P< 0.0001) at baseline, and increased to r = ∼0.6 at 3 months. The area under the ROC curve indicated a high diagnostic test yield with respect to the 1‐year outcome (area under the ROC curve ∼0.8). At all time points, including baseline, the group of patients who achieved remission at 1 year had lower average SDAI values than did those whose disease activity was high at 1 year. The groups achieving low or moderate disease activities at 1 year had SDAI values lying between. Baseline disease activity was less associated with disease activity at the end point for treatment with TNF inhibitor plus MTX, indicating its effectiveness over a broader range of baseline disease activity, but the association with end point disease activity was similar to that in the MTX treatment group at 1 month after treatment initiation. The data were similar when scores on the DAS28 and CDAI were used and were fully validated in the independent cohort of patients with late RA. Conclusion: The level of disease activity at baseline and especially during the first 3 months of treatment is significantly related to the level of disease activity at 1 year. Patients who reach a moderate or low disease activity status after 3–6 months of therapy may require switching to alternative therapies. Our findings indicate that intensive and dynamic treatment strategies that include a closer look at disease activity at 3 months in patients with early and late RA is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
The cost of dichotomising continuous variables
Altman, D. G., & Royston, P. (2006) · BMJ · doi:10.1136/bmj.332.7549.1080 · Cited by 2,688
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Self-citationvan Gestel, A. M., Prevoo, M. L. L., van't Hof, M. A., van Rijswijk, M. H., van de Putte, L. B. A., & van Riel, P. L. C. M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390105 · Cited by 1,572
Goekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Self-citationINFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Self-citationA simplified disease activity index for rheumatoid arthritis for use in clinical practice
Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., van Riel, P. L., & Tugwell, P. (2003) · Rheumatology · doi:10.1093/rheumatology/keg072 · Cited by 1,071
Self-citationAletaha, D., Nell, V. P., Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K., & Smolen, J. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1740 · Cited by 1,068
Self-citationKroot, E.-J. J. A., De Jong, B. A. W., Van Leeuwen, M. A., Swinkels, H., Van Den Hoogen, F. H. J., Van 't Hof, M., Van De Putte, L. B. A., Van Rijswijk, M. H., Van Venrooij, W. J., & Van Riel, P. L. C. M. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1831::aid-anr19>3.0.co;2-6 · Cited by 633
LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARS
Scott, D. L., Coulton, B. L., Symmons, D. P. M., & Popert, A. J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91672-2 · Cited by 594
Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states
Aletaha, D., Ward, M. M., Machold, K. P., Nell, V. P. K., Stamm, T., & Smolen, J. S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21235 · Cited by 542
Self-citationWelsing, P. M. J., Van Gestel, A. M., Swinkels, H. L., Kiemeney, L. A. L. M., & Van Riel, P. L. C. M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200109)44:9<2009::aid-art349>3.0.co;2-l · Cited by 498
Smolen, J. S., Han, C., Bala, M., Maini, R. N., Kalden, J. R., van der Heijde, D., Breedveld, F. C., Furst, D. E., Lipsky, P. E., & ATTRACT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.20982 · Cited by 462
Self-citationSmolen, J. S., Van Der Heijde, D. M. F. M., St.Clair, E. W., Emery, P., Bathon, J. M., Keystone, E., Maini, R. N., Kalden, J. R., Schiff, M., Baker, D., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21678 · Cited by 434
Self-citationDrossaers-Bakker, K. W., De Buck, M., Van Zeben, D., Zwinderman, A. H., Breedveld, F. C., & Hazes, J. M. W. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199909)42:9<1854::aid-anr9>3.0.co;2-f · Cited by 377
Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21298 · Cited by 349
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
Aletaha, D., Smolen, J., & Ward, M. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22052 · Cited by 276
Self-citationMethotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
Pincus, T., Yazıcı, Y., Sokka, T., Aletaha, D., & Smolen, J. S. (2003) · PubMed · Cited by 237
Self-citationLeeuwen, M. A. V., van der Heijde, D. M. F. M., van Rijswijk, M. H., Houtman, P. M., van Riel, P. L. C. M., van de Putte, L. B. A., & Limburg, P. C. (1994) · PubMed · Cited by 236
Early rheumatoid arthritis: time to aim for remission?
Emery, P., & Salmon, M. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.12.944 · Cited by 215
WHAT IS THE NATURAL HISTORY OF RHEUMATOID ARTHRITIS?
Pincus, T., & Callahan, L. F. (1993) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(21)00171-x · Cited by 211
Assessing remission in clinical practice
Mierau, M., Schoels, M., Gonda, G., Fuchs, J., Aletaha, D., & Smolen, J. S. (2007) · Rheumatology · doi:10.1093/rheumatology/kem007 · Cited by 200
Self-citationLeeuwen, M. A. V., van Rijswijk, M. H., Sluiter, W. J., van Riel, P. L., Kuper, I. H., van de Putte, L. B., Pepys, M. B., & Limburg, P. C. (1997) · PubMed · Cited by 190
Prognostic factors in early rheumatoid arthritis
Scott, D. L. (2000) · Rheumatology · doi:10.1093/oxfordjournals.rheumatology.a031490 · Cited by 183
Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21896 · Cited by 182
The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases
Aletaha, D., & Smolen, J. S. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.09.005 · Cited by 152
Self-citationA proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response
Felson, D. T. (2007) · Arthritis Care & Research · doi:10.1002/art.22552 · Cited by 152
Dawes, P. T., Fowler, P. D., Clarke, S., FISHER, J., LAWTON, A., & Shadforth, M. F. (1986) · Rheumatology · doi:10.1093/rheumatology/25.1.44 · Cited by 151
Quinn, M. A., Green, M. J., Marzo‐Ortega, H., Proudman, S., Karim, Z., Wakefield, R. J., Conaghan, P. G., & Emery, P. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11269 · Cited by 116
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich, K., Schett, G., Steiner, G., Hayer, S., Wagner, E., & Smolen, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11358 · Cited by 93
Self-citationArticular patterns in the early course of rheumatoid arthritis
Masi, A. T. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90471-0 · Cited by 89
Molenaar, E. T. H., Voskuyl, A. E., & Dijkmans, B. A. C. (2002) · PubMed · Cited by 76
Patients with rheumatoid arthritis in clinical care
Smolen, J. S., & Aletaha, D. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.012575 · Cited by 71
Self-citationWhich variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
Soubrier, M., Zerkak, D., Gossec, L., Ayral, X., Roux, C., & Dougados, M. (2006) · PubMed · Cited by 49
Challenges of predicting treatment response in patients with rheumatoid arthritis
Smolen, J. S., & Aletaha, D. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0050 · Cited by 29
Self-citationAletaha, D., & Smolen, J. S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21554 · Cited by 14
Self-citation
Cited by
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Self-citationSmolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citationSmolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S., Schoels, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,465
Self-citationNew therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 995
Self-citation
Metadata
- Authors
- Aletaha, D., Funovits, J., Keystone, E. C., & Smolen, J. S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-09-28
- Volume
- 56
- Issue
- 10
- Pages
- 3226-3235
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2061120890
- Cited by
- 269
- References
- 43
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.